Needham analyst Ryan Koontz maintains Twilio (NYSE:TWLO) with a Buy and lowers the price target from $350 to $200.
Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19
Virpax Pharmaceuticals Inc (NASDAQ: VRPX)
Needham Maintains Buy on Twilio, Lowers Price Target to $200
Needham analyst Ryan Koontz maintains Twilio (NYSE:TWLO) with a Buy and lowers the price target from $350 to $200.
Related Posts
Stock Wars: BJ’s Vs. Costco
Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.
Cowen & Co. Maintains Outperform on Booking Holdings, Raises Price Target to $2950
Cowen & Co. analyst Kevin Kopelman maintains Booking Holdings (NASDAQ:BKNG) with a Outperform and raises the price target from $2700 to $2950.
10 Investor Questions About COVID-19, Answered
The COVID-19 outbreak has finally subsided in the U.S., but biotech investors still have plenty of lingering questions about the virus and what to expect in the months and years ahead.
On Thursday, Bank of America analyst Geoff Meacham answered 10 of the most common COVID-19 questions he's heard as of late.